CasNo.83-43-2,Methylprednisolone CAS NO.83-43-2,(83-43-2) Suppliers

1 Metric Ton	FOB Price:USD 1.0000 -3.0000

Min.Order :1 Metric Ton
Purity: 99%
Payment Terms : L/C,T/T,Other

Keywords

83-43-2 83-43-2 Methylprednisolone Methylprednisolone

Quick Details

Appearance:crystal, powder
Application:Pharmaceutical intermediates
PackAge:as your request
ProductionCapacity:10|Metric Ton|Day
Storage:stay in dry, cool and well-sealed
Transportation:EMS,HK EMS,FEDEX,DHL,TNT

Superiority:

hebei yanxi chemical co., LTD who registered capital of 10 million yuan, nearly to $2 million, we have a pharmaceutical raw materials factory production of pharmaceutical raw materials, and a reagent r&d center, and we do research and development production of reagent tens of thousands of species. our aim is quality strives for the survival. Seek development by credit reputation. Our products have big price advantage in Europe South America and so on .and Our company also has the advantage of high quality in Africa. in the past two years our products has reached more than 30 countries in the world, Europe. South America. North America, southeast Asia, Africa, etc. We welcome all over the world with the best quality and lowest price friend common cooperation and common development!

Details:

ProName: Methylprednisolone
CasNo: 83-43-2
Molecular Formula: C22H30O5
Appearance: white or off-white crystalline powder
Application: Apply to rheumatoid arthritis, collage...
DeliveryTime: one week
PackAge: foil bags, fibre drums
Port: Shanghai
ProductionCapacity: 200 Kilogram/Month
Purity: 98%
Storage: keep in 0-6°C
Transportation: By Air
LimitNum: 100 Gram

Details

About:
Methylprednisolone is a glucocorticoid drug, used for emergency treatment of critical diseases, endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, eye diseases, gastrointestinal diseases, blood diseases, leukemia, shock, brain edema, multiple neuritis, myelitis and to prevent vomiting caused by cancer chemotherapy.

In vivo studies:
Methylprednisolone reduces RGC survival in rats with electrophysiologically diagnosed optic neuritis. Methylprednisolone reduces RGC survival by a non-genomic, calcium-dependent mechanism. Methylprednisolone induced enhancement of RGC denaturation depends on calcium inflow through volt-gated calcium channels. In beak and tail stumps, treatment with Methylprednisolone resulted in a significant reduction in the number of ED1-positive cells.

Methylprednisolone resulted in a significant reduction in tissue loss after treatment of 2,4 and 8 after one week of injury. After 1 and 2 weeks of transitional injury, Methylprednisolone resulted in long-term reduction of ED1-positive cells and loss of spinal cord tissue, reduced vestibular fiber dieback, and instantaneous germination of vestibular fibers adjacent to the lesion. In a rat model of spinal cord injury, Methylprednisolone (30mg/kg) was effective in improving functional outcomes, inhibiting TNF-α expression and NF-kB activation. Methylprednisolone inhibits the function of NF-kB, possibly induced by IKB, by trapping NF-kB in inactive cytoplasmic complexes.